- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.02. | Pila Pharma AB: Pila Pharma today publishes the Company's year-end report for the period January - December 2025. | 149 | GlobeNewswire (Europe) | The report can be found on the Company's website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
Operating income amounted to... ► Artikel lesen | |
| 26.01. | Pila Pharma AB: Pila Pharma Signs With New Clinical Cro To Prepare For Clinical Phase In Obesity After Preclinical Obesity Studies | 168 | GlobeNewswire (Europe) | Malmö, 26 January 2026
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that... ► Artikel lesen | |
| 03.11.25 | Pila Pharma share issue for obesity drug research is massively oversubscribed | 3 | The Armchair Trader | ||
| PILA PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.09.25 | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Danish preclinical Contract Research Organisation Gubra On Preclinical Trials Of Xen-d0501 In Obesity | 505 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen | |
| 27.08.25 | Pila Pharma AB: Pila Pharma Publishes Interim Report (1 January - 30 June 2025) | 517 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today publishes the Company's interim... ► Artikel lesen | |
| 31.07.25 | Pila Pharma AB: PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares | 1.139 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the last day of trading in paid subscribed units (Sw. BTU) in connection with the Company's rights issue of units which the Board... ► Artikel lesen | |
| 26.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.06.2025 | 986 | Xetra Newsboard | Das Instrument 4LG CH0371153492 LANDIS+GYR GROUP AG SF 10 EQUITY wird cum Kapitalmassnahme gehandelt am 26.06.2025 und ex Kapitalmassnahme am 27.06.2025 The instrument 4LG CH0371153492 LANDIS+GYR GROUP... ► Artikel lesen | |
| 25.06.25 | Pila Pharma AB: Pila Pharma Publishes Prospectus In Connection With The Announced Rights Issue Of Units | 258 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | -1,38 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | +0,74 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| QIAGEN | 41,295 | -0,23 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | -0,98 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | -8,25 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| TREVI THERAPEUTICS | 12,570 | +5,54 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,92 | +1,26 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| BIONTECH | 92,30 | -1,07 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 330,19 | -1,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 32,520 | -2,63 % | Tyra Biosciences GAAP EPS of -$0.57 misses by $0.04 |
Das Unternehmen PILA PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,105 Euro und damit -1,31 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.